Atherosclerosis

The supplied grounding supports low-density lipoproteins as a causal driver of atherosclerotic cardiovascular disease, with higher LDL burden associated with higher risk and lower LDL associated with lower risk. Familial hypercholesterolaemia is also supported as an inherited cause of markedly elevated LDL cholesterol and increased coronary heart disease risk. The literature additionally describes atherosclerosis as driven by traditional and nontraditional risk factors, but does not specify all of them here.

Endothelial cell dysfunction is described as an important contributor to lesion initiation and progression, affecting hemostasis, thrombosis, vascular tone, redox balance, and inflammatory signaling in the arterial wall. The disease is also framed as a chronic inflammatory process involving innate and adaptive immune responses, with signaling pathways such as NLRP3 inflammasome, toll-like receptors, PCSK9, Notch, and Wnt implicated in development and regression. Vascular smooth muscle cell phenotypic switching, proliferation, apoptosis, and senescence are also part of the plaque biology described in the grounding.

Elevated LDL burden and familial hypercholesterolaemia increase risk of atherosclerotic cardiovascular disease. The literature also refers broadly to traditional and nontraditional risk factors and to endothelial dysfunction as being related to classic and more recently defined clinical risk factors, but the supplied grounding does not enumerate them in detail. A low ankle brachial index is described as an indicator of atherosclerosis and a marker of higher cardiovascular risk.

The grounding supports LDL-lowering therapy as a central treatment approach, including LDL-lowering therapies in general and ezetimibe as a co-studied drug. It also supports prevention and control strategies focused on screening and treatment of familial hypercholesterolaemia to prevent coronary heart disease. Inflammatory pathway targeting is discussed as a therapeutic direction, including interventions aimed at the NLRP3 inflammasome and interleukin-1β, but the supplied material does not establish a full standard regimen.